437 related articles for article (PubMed ID: 15558054)
1. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.
Issaeva N; Bozko P; Enge M; Protopopova M; Verhoef LG; Masucci M; Pramanik A; Selivanova G
Nat Med; 2004 Dec; 10(12):1321-8. PubMed ID: 15558054
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
[TBL] [Abstract][Full Text] [Related]
3. Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer.
Espinoza-Fonseca LM
Theor Biol Med Model; 2005 Sep; 2():38. PubMed ID: 16174299
[TBL] [Abstract][Full Text] [Related]
4. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
[TBL] [Abstract][Full Text] [Related]
5. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.
Spinnler C; Hedström E; Li H; de Lange J; Nikulenkov F; Teunisse AF; Verlaan-de Vries M; Grinkevich V; Jochemsen AG; Selivanova G
Cell Death Differ; 2011 Nov; 18(11):1736-45. PubMed ID: 21546907
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
Jones RJ; Bjorklund CC; Baladandayuthapani V; Kuhn DJ; Orlowski RZ
Mol Cancer Ther; 2012 Oct; 11(10):2243-53. PubMed ID: 22933706
[TBL] [Abstract][Full Text] [Related]
7. Cancer drug discovery: the wisdom of imprecision.
Gudkov AV
Nat Med; 2004 Dec; 10(12):1298-9. PubMed ID: 15580251
[No Abstract] [Full Text] [Related]
8. RITA enhances chemosensivity of pre-B ALL cells to doxorubicin by inducing p53-dependent apoptosis.
Kazemi A; Safa M; Shahbazi A
Hematology; 2011 Jul; 16(4):225-31. PubMed ID: 21756539
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific induction of apoptosis by a p53-reactivating compound.
Hedström E; Issaeva N; Enge M; Selivanova G
Exp Cell Res; 2009 Feb; 315(3):451-61. PubMed ID: 19071110
[TBL] [Abstract][Full Text] [Related]
10. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.
Zhao CY; Grinkevich VV; Nikulenkov F; Bao W; Selivanova G
Cell Cycle; 2010 May; 9(9):1847-55. PubMed ID: 20436301
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
Chène P
Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
[TBL] [Abstract][Full Text] [Related]
12. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53.
Higashitsuji H; Higashitsuji H; Itoh K; Sakurai T; Nagao T; Sumitomo Y; Masuda T; Dawson S; Shimada Y; Mayer RJ; Fujita J
Cancer Cell; 2005 Jul; 8(1):75-87. PubMed ID: 16023600
[TBL] [Abstract][Full Text] [Related]
13. Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma.
Saha MN; Jiang H; Yang Y; Zhu X; Wang X; Schimmer AD; Qiu L; Chang H
PLoS One; 2012; 7(1):e30215. PubMed ID: 22276160
[TBL] [Abstract][Full Text] [Related]
14. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
15. Mdm2-P53 Interaction Inhibitor with Cisplatin Enhances Apoptosis in Colon and Prostate Cancer Cells In-Vitro.
Gupta A; Behl T; Heer HR; Deshmukh R; Sharma PL
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3341-3351. PubMed ID: 31759358
[TBL] [Abstract][Full Text] [Related]
16. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
[TBL] [Abstract][Full Text] [Related]
17. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
Di Conza G; Buttarelli M; Monti O; Pellegrino M; Mancini F; Pontecorvi A; Scotlandi K; Moretti F
Mol Cancer Ther; 2012 Jun; 11(6):1247-56. PubMed ID: 22461661
[TBL] [Abstract][Full Text] [Related]
18. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38.
Weilbacher A; Gutekunst M; Oren M; Aulitzky WE; van der Kuip H
Cell Death Dis; 2014 Jul; 5(7):e1318. PubMed ID: 25010984
[TBL] [Abstract][Full Text] [Related]
19. Efficient synthesis of RITA and its analogues: derivation of analogues with improved antiproliferative activity via modulation of p53/miR-34a pathway.
Lin J; Jin X; Bu Y; Cao D; Zhang N; Li S; Sun Q; Tan C; Gao C; Jiang Y
Org Biomol Chem; 2012 Dec; 10(48):9734-46. PubMed ID: 23151607
[TBL] [Abstract][Full Text] [Related]
20. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]